Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics' stock has experienced a significant increase of 136.21% over the past year. In December 2025, the company announced a proposed $150.0 million public offering of common stock, which was later upsized to $175.0 million and reported positive initial results from the Phase 1b PIONEER trial of pociredir in sickle cell disease. Analyst ratings have been generally positive, with a consensus of "Moderate Buy". Insider selling has occurred, with Director Robert J. Gould selling 15,000 shares in January 2026. In May 2025, the company reported its Q1 2025 financial results, with a net loss improving to $17.7 million. In October 2025, Fulcrum reported compelling data from the 12 mg dose cohort of the PIONEER trial for pociredir in sickle cell disease.

Information regarding the demand seasonality for Fulcrum Therapeutics, Inc.'s products and services is not available. Its revenue generation is primarily tied to the successful development and commercialization of its drug candidates.

Fulcrum Therapeutics, Inc. (FULC) is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for genetically defined rare diseases with unmet medical needs. Their lead program is pociredir for sickle cell disease (SCD) and beta-thalassemia. They also have programs targeting inherited aplastic anemias, novel HbF inducers, fibrotic disorders, and cardiomyopathies. The development of Losmapimod for facioscapulohumeral muscular dystrophy (FSHD) was suspended after unsuccessful trial results in September 2024.

Fulcrum Therapeutics is headquartered in Cambridge, Massachusetts, United States.

Specific events directly impacting Fulcrum Therapeutics' brand reputation in the past year are not explicitly detailed. Positive clinical data for pociredir in sickle cell disease would generally enhance its reputation. The suspension of the losmapimod development program in September 2024 could have negatively impacted its reputation. The company's focus on genetically defined rare diseases and its proprietary technology contribute to its scientific standing.

Fulcrum Therapeutics, Inc. is predominantly owned by institutional shareholders, holding 99.37% of the stock. Major institutional owners include Ra Capital Management, L.P., Suvretta Capital Management, LLC, and TCG Crossover Management, LLC. Individual insiders own 1.23% of the company's stock.